The Trump administration has reached new drug-pricing agreements with nine pharmaceutical companies, including Teva Pharmaceuticals and Astellas Pharma, as part of its effort to lower prescription costs in the United States.
Under the agreements, the companies will offer medicines to state Medicaid programs at “most-favored-nation” prices, meaning prices comparable to the lowest rates paid in other developed countries. The latest deals bring the total number of pharmaceutical companies participating in the administration's pricing initiative to 26, covering about 89% of the U.S. branded-drug market.
The agreements build on earlier deals with major drugmakers such as Pfizer, Eli Lilly and Amgen. In return for lower prices, participating companies may receive benefits including protection from certain pharmaceutical tariffs.
The administration has projected substantial savings from its broader pricing campaign, although the actual savings for patients and government programs remain uncertain. Medicaid already receives significant discounts under existing law, meaning the effect on consumers could vary depending on the drug and coverage arrangement.
Related Tweet:
U.S. President Donald Trump announced a new round of drug-pricing agreements with international pharmaceutical companies and some smaller biotechs on Monday, part of a push to make healthcare more affordable for Americans. https://t.co/pG6pxwcpNG
— Reuters Legal (@ReutersLegal) August 31, 2026
Also Read:
TIPP Staff
